Scientific journal
International Journal of Applied and fundamental research
ISSN 1996-3955
ИФ РИНЦ = 0,593

Personal portfolio

2 2 2 2 3
2 Institute of Bioorganic Chemistry, RAS
3 Roentgenoradiology Center
Earlier, we demonstrated the prognostic value of some routine laboratory parameters to determine early or late visible mammary carcinoma manifestation and interleukin-2 (IL-2) efficacy in mouse recipients with only early emerging transplanted mammary cancer. Therefore, 17 hematological parameters were prospectively measured in intact BLRB males before mammary carcinoma inoculation and IL-2 application. Five hematological pa-rameters pointed to anemia and leucopenia prior to mammary carcinoma inoculation predicted short survival of tumorbearing mice treated twice with 2x105 ME of IL-2 at days 13 and 22 post tumor transplantation. However, in non-treated controls these blood parameter values did not differ among short and long survivors. These results demonstrated that initial poor physical condition of mice before mammary cancer transplantation can limit the efficacy of immunotherapy applied to tumor bearing mice with early mammary carcinoma manifestation.
breast cancer
mouse model
prognostic factors
immunotherapy
interleukin-2
1. Moiseyeva E.: Antibreast cancer drug testing. Original Approaches. Novel Set of Mouse Models. Lambert Ac. Publ., (2009), p.p. 220
2. Grande C., Firvida J.L., Navas V., Casal J. (2006) Anticancer Drugs, 17, 1-12
3. Nicolini A., Carpi A. (2009) Med Res Rev, 29, 436-471
4. Moiseyeva E.V., Semushina S.G., Chaadaeva A.V., Kessler Yu.V. (2010) Int J Appl Fundam Res, 10, in publication
5. Moiseyeva E.V., Merkulova I.B., Bijleveld C., Koten J.W., Miroshnikov A.I., Den Otter W. (2003) Cancer Immunol Immunother, 52, 487-496
6. Moiseyeva E.V., Bojenko V.K., Fomina G.G., Krasnovskaya O.R., Krasilshchikova M.S., Den Otter W. (2002) Baltic J Lab Anim Sci, 12, 74-83
7. Moiseyeva E.V., Rapoport E.M., Bovin N.V., Miroshnikov A.I., Chaadaeva A.V., Krasilshchikova M.S., Bojenko V.K., Bijleveld C., van Dijk J.E., Den Otter W. (2005) Breast Cancer Res Treat, 91, 227-241
8. Kedar E., Klein E. (1992) Adv Cancer Res, 59, 245-322